[11C]Choline-PET/CT for outcome prediction of salvage radiotherapy of local relapsing prostate carcinoma

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 56, Issue 5, 2012, Pages 430-439

  Reske, S N ^a   Moritz, S ^a   Kull, T ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Prostatic neoplasms; Radiotherapy; Recurrence

Indexed keywords

CHOLINE C 11; IOPROMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED RADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; IMAGE ANALYSIS; MALE; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN BLOOD LEVEL; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; CARBON RADIOISOTOPES; CHOLINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SALVAGE THERAPY;

EID: 84871768913     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Freedland SJ, Presti JR JC, Amling CL, Kane CJ, Aronson WJ, Dorey F et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology 2003;61:736-41. (Pubitemid 36384965)
2. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-23. (Pubitemid 36132976)
3. Patel AR, Stephenson AJ. Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage? Nat Rev Urol 2011;8:385-92.
4. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406. (Pubitemid 27169264)
5. Stephenson AJ, Wood DP, Kattan MW, Klein EA, Scardino PT, Eastham JA et al. Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol 2009;182:1357-63.
6. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71.
7. 11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl MEd Mol Imaging 2008;35:9-17.
8. Reske SN. Nuclear imaging of prostate cancer: current status. Urologe A 2007;46:1485-99. (Pubitemid 350132140)
9. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 2011;59:51-60.
10. Beer AJ, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol 2011;12:181-91.
11. Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 2006;47:1249-54. (Pubitemid 47544875)
12. 11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression. Clin Cancer Res 2011;17:7673-83.
13. Souvatzoglou M, Krause BJ, Purschel A, Thamm R, Schuster T, Buck AK et al. Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol 2011;99:193-200.
14. Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L etal. [(11)C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 2012;39:13-26.
15. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 2010;12:98-107.
16. Giovacchini G, Picchio M, Briganti A, Cozzarini C, Scattoni V, Salonia A et al. [11C]choline positron emission tomography/ computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol 2010;184:938-43.
17. Urologie DGf. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms 2009:34-51.
18. Morris MM, Dallow KC, Zietman AL, Parc J, Althausen A, Heney NM et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 1997;38:731-6. (Pubitemid 27310541)
19. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035-41. (Pubitemid 46972788)
20. Wilson AA, Garcia G, Jin L, Houle S. Radiotracer synthesis from [11C]-iodomethane: a remarkably simple captive solvent method. Nucl Med Biol 2000;27:529-32.
21. Schmidt DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW et al. Fluorcholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005;235:623-8. (Pubitemid 40571106)
22. Choo R. Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges. Cancer Res Treat 2010;42:1-11.
23. Hricak H, Schoder H, Pucar D, Lis E, Eberhardt SC, Onyebuchi CN et al Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Semin Oncol 2003;30:616-34. (Pubitemid 37296787)
24. Akin O, Hricak H. Imaging of prostate cancer. Radiol Clin North Am 2007;45:207-22. (Pubitemid 44854046)
25. Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 2007;99:1415-20. (Pubitemid 47164795)
26. Bottke D, de Reijke TM, Bartkowiak D, Wiegel T. Salvage radiotherapy in patients with persisting/rising PSA after radical prostatectomy for prostate cancer. Eur J Cancer 2009;45(Suppl 1):148-57.
27. Wiegel T, Lohm G, Bottke D, Hocht S, Miller K, Siegmann A et al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome - results of a retrospective study. Int J Radiat Oncol Biol Phys 2009;73:1009-16.